Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 492

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

Open access
Hanley, Daniel F, Lane, Karen, McBee, Nichol, Ziai, Wendy, Tuhrim, Stanley, Lees, Kennedy R, Dawson, Jesse, Gandhi, Dheeraj, Ullman, Natalie, Mould, W Andrew, Mayo, Steven W, Mendelow, A David, Gregson, Barbara, Butcher, Kenneth, Vespa, Paul, Wright, David W, Kase, Carlos S, Carhuapoma, J Ricardo, Keyl, Penelope M, Diener-West, Marie, Muschelli, John, Betz, Joshua F, Thompson, Carol B, Sugar, Elizabeth A, Yenokyan, Gayane, Janis, Scott, John, Sayona, Harnof, Sagi, Lopez, George A, Aldrich, E Francois, Harrigan, Mark R, Ansari, Safdar, Jallo, Jack, Caron, Jean-Louis, LeDoux, David, Adeoye, Opeolu, Zuccarello, Mario, Adams, Harold P, Rosenblum, Michael, Thompson, Richard E, Awad, Issam A·2017·The Lancet

Abstract

Summary Background Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome. Methods In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0·9% saline via the extraventricular drain. The treating physician, clinical research staff, and participants were masked to treatment assignment. CT scans were obtained every 24 h throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 days per central adjudication by blinded evaluators. This study is registered with ClinicalTrials.gov, NCT00784134. Findings Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group. 180-day follow-up data were available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. The primary efficacy outcome was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1·06 [95% CI 0·88–1·28; p=0–554]). A difference of 3·5% (RR 1·08 [95% CI 0·90–1·29], p=0–420) was found after adjustment for intraventricular haemorrhage size and thalamic intracerebral haemorrhage. At 180 days, the treatment group had lower case fatality (46 [18%] vs saline 73 [29%], hazard ratio 0·60 [95% CI 0·41–0·86], p=0–006), but a greater proportion with mRS 5 (42 [17%] vs 21 [9%]; RR 1·99 [95% CI 1·22–3·26], p=0–007). Ventriculitis (17 [7%] alteplase vs 31 [12%] saline; RR 0·55 [95% CI 0·31–0·97], p=0–048) and serious adverse events (114 [46%] alteplase vs 151 [60%] saline; RR 0·76 [95% CI 0·64–0·90], p=0–002) were less frequent with alteplase treatment. Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1·21 [95% CI 0·37–3·91], p=0–771) was similar. Interpretation In patients with intraventricular haemorrhage and a routine extraventricular drain, irrigation with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with irrigation with saline. Protocol-based use of alteplase with extraventricular drain seems safe. Future investigation is needed to determine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produces gains in functional status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)32410-2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 492

Metadata

Authors
Hanley, D. F., Lane, K., McBee, N., Ziai, W., Tuhrim, S., Lees, K. R., Dawson, J., Gandhi, D., Ullman, N., Mould, W. A., Mayo, S. W., Mendelow, A. D., Gregson, B., Butcher, K., Vespa, P., Wright, D. W., Kase, C. S., Carhuapoma, J. R., Keyl, P. M., Diener-West, M., Muschelli, J., Betz, J. F., Thompson, C. B., Sugar, E. A., Yenokyan, G., Janis, S., John, S., Harnof, S., Lopez, G. A., Aldrich, E. F., Harrigan, M. R., Ansari, S., Jallo, J., Caron, J.-L., LeDoux, D., Adeoye, O., Zuccarello, M., Adams, H. P., Rosenblum, M., Thompson, R. E., & Awad, I. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-02
Volume
389
Issue
10069
Pages
603-611
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2549926987
Cited by
492
References
21
FWCI
30.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)32410-2
The paper
Hanley, D. F., Lane, K., McBee, N., Ziai, W., Tuhrim, S., Lees, K. R., Dawson, J., Gandhi, D., Ullman, N., Mould, W. A., Mayo, S. W., Mendelow, A. D., Gregson, B., Butcher, K., Vespa, P., Wright, D. W., Kase, C. S., Carhuapoma, J. R., Keyl, P. M., . . . Awad, I. A. (2017). Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)32410-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.